Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer
Publication in refereed journal


Times Cited
Altmetrics Information
.

Other information
AbstractThe use of targeted therapy in the management of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer is an important milestone in the management of advanced lung cancer. There are several generations of EGFR tyrosine kinase inhibitors available for clinical use. Dacomitinib is a second-generation irreversible EGFR tyrosine kinase inhibitor with early-phase clinical studies showing efficacy in non-small-cell lung cancer. In the recently published ARCHER 1050 phase III study, dacomitinib given at 45mg/day orally was superior to gefitinib, a first-generation reversible EGFR tyrosine kinase inhibitor, in improving both progression-free survival and overall survival when given as first-line therapy. There is no prospective evidence to support the use of dacomitinib as subsequent therapy in patients previously treated with chemotherapy or a first-generation EGFR tyrosine kinase inhibitor such as gefitinib and erlotinib. Dacomitinib has not demonstrated any benefit in unselected patients with non-small-cell lung cancer, and its use should be limited to those with known EGFR-sensitizing mutations. Dacomitinib is associated with increased toxicities of diarrhea, rash, stomatitis, and paronychia compared with first-generation EGFR inhibitors. Global quality of life was maintained when assessed in phase III studies. Overall, dacomitinib is an important first- line agent in EGFR-mutated non-small-cell lung cancer in otherwise fit patients whose toxicities can be well managed.
All Author(s) ListLau SCM, Batra U, Mok TSK, Loong HH
Journal nameDrugs
Year2019
Month6
Volume Number79
Issue Number8
PublisherSpringer
Place of PublicationNew Zealand
Pages823 - 831
ISSN0012-6667
eISSN1179-1950
LanguagesEnglish-United Kingdom
KeywordsNSCLC

Last updated on 2019-03-12 at 00:17